Legend Biotech (LEGN) news
Recent news
Legend Biotech Corp.: Oppenheimer cuts to perform from outperform
AInvest Wire · Aug 12, 2026Legend Biotech: Barclays cuts target price to $78 from $80
Barclays analyst Etzer Darout has revised the price target for Legend Biotech (NASDAQ:LEGN) to $78 from $80, while maintaining a Buy rating . The adjustment reflects a reassessment of near-term expectations, despite the firm's confidence in the clinical pipeline . Legend Biotech, a leader in CAR-T…
AInvest Wire · Aug 12, 2026Legend Biotech shares rise 1.2% after Q2 revenue beat
Legend Biotech Corporation (NASDAQ: LEGN) shares rose 1.2% following the release of its first-quarter 2026 financial results, which showed stronger-than-expected revenue performance. The company reported collaboration revenue of $298.4 million , a significant increase from $185.6 million in the…
AInvest Wire · Aug 11, 2026Legend Biotech shares rise 4.1% premarket after Q2 revenue beat
Legend Biotech (LEGND) shares rose 4.1% in premarket trading on August 11, 2026, following the release of second-quarter financial results that showed revenue above expectations. The company reported Q2 revenue of $115 million , surpassing the consensus estimate of $108 million. This marks a 12%…
AInvest Wire · Aug 11, 2026Legend Biotech Corporation Q2 revenue USD 387.5 million vs. IBES estimate USD 355.8 million
AInvest Wire · Aug 11, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.